PlexusDx review

PlexusDx is easy to misfile as a DNA-testing company, and it is not. Underneath the "built around your genetics" positioning sits a conventional prescription peptide service with five longevity protocols and a published all-in monthly price on each: NAD⁺ and sermorelin from $129, glutathione at $125, GHK-Cu Rx at $139 and PT-141 at $189. Consultation, medication, shipping and ongoing provider monitoring are stated as included, which is what "all-inclusive" should mean. Read the NAD⁺ and sermorelin figures carefully, though: $129 is the six-month commitment rate, and month-to-month is $179. The genetics part is a $99 add-on offered after your first month — an upsell, not an input to your prescription.

PlexusDx is a US telehealth platform running two prescription lines alongside a genetic-testing and blood-testing business. Weight loss covers five compounded GLP-1 protocols — a microdose GLP-1 from $129/mo, semaglutide from $149/mo and tirzepatide from $249/mo, in injection or oral form. Longevity covers five single-compound protocols: NAD⁺ (injection, nasal spray or a dissolving tablet), sermorelin (injection or orally disintegrating troche), glutathione (nasal spray or troche), GHK-Cu Rx as a topical cream, and PT-141. Its genetic side sells methylation, peptide-pathway and other reports from a cheek swab. A licensed clinician from an independent network reviews each intake, and compounded medication comes from licensed 503A pharmacies.

Asynchronous in most states, program-shaped, and clearer than most about what a price covers. Each protocol is labeled all-inclusive — consultation, prescription, medication, shipping, ongoing provider monitoring and provider-reviewed refills — with no membership fee, and it states that five states require a live video consultation while the rest allow an online intake. It displays an HSA/FSA payment option through Flex and says you can cancel from a self-service portal before your next billing cycle, with no fee. Two things to keep in view. First, the genetics framing does real work in the marketing and very little in the care pathway: the Precision Peptide genetic test is sold as a $99 add-on against a $298 list price, offered after your first month of treatment, so nothing about your initial prescription is genetically informed unless you separately buy in. Second, the compounding pharmacies are never named — only described as licensed 503A pharmacies — and no individual clinician or medical director is published. Its own fine print also notes that medication and clinical fees are billed by the practice-management platform behind the prescribers rather than by PlexusDx itself, so expect that name on your card statement.

Published per protocol and stated as all-inclusive. NAD⁺ and sermorelin are each priced by commitment tier: $179 a month month-to-month, $149 on a three-month commitment and $129 on six months, the same price at every dose and in every formulation. Glutathione is a flat $125, GHK-Cu Rx a flat $139 and PT-141 a flat $189. The Longevity headline, "starts at $125/mo", is the glutathione price. A GETSTARTED code takes 10% off a first protocol for new patients. On the weight-loss side, protocols run $129 to $279 a month at their best commitment tier — but those are GLP-1 figures and are not peptide or NAD⁺ prices. The genetic test is a separate $99 charge after your first month, discounted from a stated $298; treat that as an add-on, not as a bundled benefit. Ask what the monthly shipment contains, since neither dose nor vial size is stated beside any protocol price.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. PlexusDx states in its own words that its compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality, that it does not sell branded medication (though a provider can write a branded prescription for you to fill elsewhere), and that medication comes from licensed 503A pharmacies — none of which it names. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On evidence, the five longevity protocols are not five equivalent purchases. Sermorelin is a GHRH analog with a real mechanism and thin long-term human outcome data. Injected and intranasal NAD⁺ have no controlled human outcome trials; the oral precursors NR and NMN are the forms with human data and they raise a blood level. GHK-Cu and glutathione have essentially no controlled human outcome data. PT-141 is approved for one narrow indication in premenopausal women, so other prescribing is off-label. Individual results vary.